Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
The HER-2/ neu oncogene is a member of the erb B-like oncogene family, and is related to, but distinct from, the epidermal growth factor receptor. This gene has been shown to be amplified in human breast cancer cell lines. In the current study, alterations of the gene in 189 primary human breast cancers were investigated. HER-2/ neu was found to be amplified from 2- to greater than 20-fold in 30% of the tumors. Correlation of gene amplification with several disease parameters was evaluated. Amplification of the HER-2/ neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer. It retained its significance even when adjustments were made for other known prognostic factors. Moreover, HER-2/ neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal-receptor status, in lymph node-positive disease. These data indicate that this gene may play a role in the biologic behavior and/or pathogenesis of human breast cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CNVs are involved in a large number of complex human diseases such as Down’s syndrome (trisomy 21) and many cancers, for example HER2 gene amplification in breast cancer (BC) (1–5).”
From Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation (2012) · cites this paper as [5]
In the citing paper
“In a seminal study, Slamon et al. found that HER2 is amplified in about 20% of breast cancers (Slamon et al., 1987).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Slamon et al., 1987
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene
Greenberg, M. E., & Ziff, E. B. (1984) · Nature · doi:10.1038/311433a0 · Cited by 3,064
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804
Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., et al. (1984) · Nature · doi:10.1038/309418a0 · Cited by 2,752
Self-citationClose similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences
Downward, J., Yarden, Y., Mayes, E., Scrace, G., Totty, N., Stockwell, P., Ullrich, A., Schlessinger, J., & Waterfield, M. D. (1984) · Nature · doi:10.1038/307521a0 · Cited by 2,516
Self-citationAmplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage
Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E., & Bishop, J. M. (1984) · Science · doi:10.1126/science.6719137 · Cited by 2,262
Association of Multiple Copies of the N-myc Oncogene with Rapid Progression of Neuroblastomas
Seeger, R. C., Brodeur, G. M., Sather, H., Dalton, A., Siegel, S. E., Wong, K. Y., & Hammond, D. (1985) · New England Journal of Medicine · doi:10.1056/nejm198510313131802 · Cited by 2,010
Coussens, L., Yang-Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985) · Science · doi:10.1126/science.2999974 · Cited by 1,814
Self-citation
Research works printed but not linked: 1
- Maniatis, T., Molecular Cloning: A Laboratory Manual: 282 (1982).
Cited by
Items 101–200 of 1,056
Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.
Berchuck, A., Kamel, A., Whitaker, R. S., Kerns, B. J., Olt, G. J., Kinney, R., Soper, J. T., Dodge, R. K., Clarke‐Pearson, D. L., & Marks, P. J. (1990) · PubMed · Cited by 860
Mehta, L. S., Watson, K. E., Barac, A., Beckie, T. M., Bittner, V., Cruz-Flores, S., Dent, S., Kondapalli, L., Ky, B., Okwuosa, T., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000556 · Cited by 848
Kaufman, B., Mackey, J. R., Clemens, M. R., Bapsy, P. P., Vaid, A., Wardley, A., Tjulandin, S., Jahn, M., Lehle, M., Feyereislova, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6847 · Cited by 843
Cardiovascular Complications of Cancer Therapy: Diagnosis, Pathogenesis, and Management
Yeh, E. T. H., Tong, A. T., Lenihan, D. J., Yusuf, S. W., Swafford, J., Champion, C., Durand, J.-B., Gibbs, H., Zafarmand, A. A., & Ewer, M. S. (2004) · Circulation · doi:10.1161/01.cir.0000133187.74800.b9 · Cited by 843
Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis
Karantza-Wadsworth, V., Patel, S., Kravchuk, O., Chen, G., Mathew, R., Jin, S., & White, E. (2007) · Genes & Development · doi:10.1101/gad.1565707 · Cited by 841
Antibody–drug conjugates for cancer
Chau, C. H., Steeg, P. S., & Figg, W. D. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31774-x · Cited by 816
Padua, D., & Massagué, J. (2009) · Cell Research · doi:10.1038/cr.2008.316 · Cited by 809
Tan-Chiu, E., Yothers, G., Romond, E., Geyer, C. E., Ewer, M., Keefe, D., Shannon, R. P., Swain, S. M., Brown, A., Fehrenbacher, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.4091 · Cited by 808
Intragenic ERBB2 kinase mutations in tumours
Stephens, P., Hunter, C., Bignell, G., Edkins, S., Davies, H., Teague, J., Stevens, C., O'Meara, S., Smith, R., Parker, A., et al. (2004) · Nature · doi:10.1038/431525b · Cited by 802
Press, M. F., Bernstein, L., Thomas, P. A., Meisner, L. F., Zhou, J. Y., Ma, Y., Hung, G., Robinson, R. A., Harris, C., El-Naggar, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.8.2894 · Cited by 802
Self-citationMolecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
Force, T., Krause, D. S., & Van Etten, R. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2106 · Cited by 801
Cameron, D., Casey, M., Press, M., Lindquist, D., Pienkowski, T., Romieu, C. G., Chan, S., Jagiello-Gruszfeld, A., Kaufman, B., Crown, J., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9885-0 · Cited by 794
“HER2 amplification occurs in approximately 20% of invasive breast cancers and confers a more aggressive phenotype [ 2 , 3]. Therapeutic strategies have been developed to block HER2 signalling pathways, including monoclonal antibodies (MoAbs) and small molecule tyrosine kinase inhibitors (TKIs).”
BackgroundNahta, R., Yuan, L. X. H., Zhang, B., Kobayashi, R., & Esteva, F. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3841 · Cited by 793
“The her-2 (erbB2/neu) gene is amplified and/or overexpressed in f20% to 30% of invasive breast carcinomas and is associated with increased metastatic potential and decreased overall survival (1).”
BackgroundCheng, J. Q., Ruggeri, B., Klein, W. M., Sonoda, G., Altomare, D. A., Watson, D. K., & Testa, J. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3636 · Cited by 793
HER2-Low Breast Cancer: Pathological and Clinical Landscape
Tarantino, P., Hamilton, E., Tolaney, S. M., Cortes, J., Morganti, S., Ferraro, E., Marra, A., Viale, G., Trapani, D., Cardoso, F., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02488 · Cited by 791
Reedijk, M., Odorcic, S., Chang, L., Zhang, H., Miller, N., McCready, D. R., Lockwood, G., & Egan, S. E. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1069 · Cited by 783
“Schematic diagram of DSL Notch ligands (Jagged1,2, Delta1,3,4) and Notch receptors (1-4).”
BackgroundThe ras gene family and human carcinogenesis
Bos, J. L. (1988) · Mutation Research/Reviews in Genetic Toxicology · doi:10.1016/0165-1110(88)90004-8 · Cited by 782
Hortobagyi, G. N. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810013391407 · Cited by 781
Strategies for discovering novel cancer biomarkers through utilization of emerging technologies
Kulasingam, V., & Diamandis, E. P. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1187 · Cited by 771
“HER2 is a cell membrane surface-bound tyrosine kinase that is involved in cell growth and differentiation”
BackgroundAnti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park, J. W., Hong, K., Kirpotin, D. B., Colbern, G. T., Shalaby, R., Baselga, J. M., Shao, Y. Y., Nielsen, U. B., Marks, J. D., Moore, D. H., et al. (2002) · Clinical Cancer Research · Cited by 766
Dawood, S., Broglio, K., Buzdar, A. U., Hortobagyi, G. N., & Giordano, S. H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9844 · Cited by 758
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
Tolaney, S. M., Barry, W. T., Dang, C. T., Yardley, D. A., Moy, B., Marcom, P. K., Albain, K. S., Rugo, H. S., Ellis, M., Shapira, I., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406281 · Cited by 753
The epidermal growth factor receptor family: Biology driving targeted therapeutics
Wieduwilt, M. J., & Moasser, M. M. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7440-8 · Cited by 751
The transcriptional repressor Snail promotes mammary tumor recurrence
Moody, S. E., Perez, D., Pan, T.-C., Sarkisian, C. J., Portocarrero, C. P., Sterner, C. J., Notorfrancesco, K. L., Cardiff, R. D., & Chodosh, L. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.07.009 · Cited by 750
“Amplification and overexpression of this receptor tyrosine kinase occurs in 15%–30% of primary human breast cancers and is associated with aggressive tumor behavior, high rates of relapse, and poor prognosis (Berger et al., 1988; Slamon et al., 1987).”
BackgroundReovirus Therapy of Tumors with Activated Ras Pathway
Coffey, M. C., Strong, J. E., Forsyth, P. A., & Lee, P. W. K. (1998) · Science · doi:10.1126/science.282.5392.1332 · Cited by 750
Hudziak, R. M., Lewis, G. D., Winget, M., Fendly, B. M., Shepard, H. M., & Ullrich, A. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.3.1165 · Cited by 749
“(35) surveyed 189 primary breast adenocarcinomas and determined that the HER21c-erbB-2 gene was amplified in about 30% of the cases.”
BackgroundSelf-citationTumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers
Hayes, D. F., Bast, R. C., Desch, C. E., Fritsche, H., Kemeny, N. E., Jessup, J. M., Locker, G. Y., Macdonald, J. S., Mennel, R. G., Norton, L., et al. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.20.1456 · Cited by 748
The two faces of transforming growth factor β in carcinogenesis
Roberts, A. B., & Wakefield, L. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1633291100 · Cited by 747
Kallioniemi, A., Kallioniemi, O. P., Piper, J., Tanner, M., Stokke, T., Chen, L., Smith, H. S., Pinkel, D., Gray, J. W., & Waldman, F. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.6.2156 · Cited by 739
Biology of HER2 and Its Importance in Breast Cancer
Yarden, Y. (2001) · Oncology · doi:10.1159/000055396 · Cited by 737
“HER2 amplification was first noted in human breast cancer and was subsequently identified in ovarian cancer [Berchuck et al. 1990; Slamon et al. 1987, 1989; Zhang et al. 1989].”
BackgroundBachelot, T., Romieu, G., Campone, M., Diéras, V., Cropet, C., Dalenc, F., Jimenez, M., Le Rhun, E., Pierga, J.-Y., Gonçalves, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70432-1 · Cited by 737
Cheng, J. Q., Godwin, A. K., Bellacosa, A., Taguchi, T., Franke, T. F., Hamilton, T. C., Tsichlis, P. N., & Testa, J. R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.19.9267 · Cited by 736
A quantitative protein interaction network for the ErbB receptors using protein microarrays
Jones, R. B., Gordus, A., Krall, J. A., & MacBeath, G. (2006) · Nature · doi:10.1038/nature04177 · Cited by 727
Ewer, M. S., Vooletich, M. T., Durand, J.-B., Woods, M. L., Davis, J. R., Valero, V., & Lenihan, D. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.300 · Cited by 726
Ota, A., Tagawa, H., Karnan, S., Tsuzuki, S., Karpas, A., Kira, S., Yoshida, Y., & Seto, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3773 · Cited by 724
Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J.-H., Davidson, N. E., Geyer, C. E., Martino, S., Mamounas, E. P., Kaufman, P. A., & Wolmark, N. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.0868 · Cited by 717
“HER2-positive breast tumors are more aggressive and more susceptible to recurrence than HER2normal tumors.(4,5) In the metastatic setting, trastuzumab provides significant clinical benefit as monotherapy and in combination with chemotherapy as either first- or second-line therapy.”
BackgroundCNS Metastases in Breast Cancer
Lin, N. U., Bellon, J. R., & Winer, E. P. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.175 · Cited by 715
Plowman, G. D., Culouscou, J. M., Whitney, G. S., Green, J. M., Carlton, G. W., Foy, L., Neubauer, M. G., & Shoyab, M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1746 · Cited by 713
Yakes, F. M., Chinratanalab, W., Ritter, C. A., King, W., SEELIG, S. A., & Arteaga, C. L. (2002) · PubMed · Cited by 705
Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity.
Guy, P. M., Platko, J. V., Cantley, L. C., Cerione, R. A., & Carraway, K. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.17.8132 · Cited by 698
Qiu, F. H., Ray, P., Brown, K., Barker, P. E., Jhanwar, S., Ruddle, F. H., & Besmer, P. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb02907.x · Cited by 697
Pegram, M., Hsu, S., Lewis, G., Pietras, R., Beryt, M., Sliwkowski, M., Coombs, D., Baly, D., Kabbinavar, F., & Slamon, D. (1999) · Oncogene · doi:10.1038/sj.onc.1202526 · Cited by 692
“…p185HER-2/neu, resulting from amplification of the HER-2/neu gene, is associated with poor clinical outcome in 25 ± 30% of carcinomas of the breast (Slamon et al., 1987), as well as in other human malignancies (Semba et al., 1985; Slamon et al., 1989; Berchuck et al., 1991; Yonemura et al.,…”
BackgroundSelf-citationLee, M. J., Ye, A. S., Gardino, A. K., Heijink, A. M., Sorger, P. K., MacBeath, G., & Yaffe, M. B. (2012) · Cell · doi:10.1016/j.cell.2012.03.031 · Cited by 680
“Moreover, the identification of molecular drivers in specific breast cancer subtypes has led to the development of more efficacious forms of targeted therapy (Schechter et al., 1984; Slamon et al., 1987).”
BackgroundModelling breast cancer: one size does not fit all
Vargo-Gogola, T., & Rosen, J. M. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2193 · Cited by 679
“Not surprisingly, TP53 , which is one of the most frequently mutated genes in breast cancer, and ERBB2 , which is amplified in 25–30% of human breast cancers, have been studied most extensivel”
BackgroundSomatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas
Shigematsu, H., Takahashi, T., Nomura, M., Majmudar, K., Suzuki, M., Lee, H., Wistuba, I. I., Fong, K. M., Toyooka, S., Shimizu, N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4235 · Cited by 678
“States (157) Female (72) 0 S (117) 0 Others (60) 0 Australia 13 (13) 12 (12) 1 (1.”
BackgroundErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.
Karunagaran, D., Tzahar, E., Beerli, R. R., Chen, X., Graus-Porta, D., Ratzkin, B. J., Seger, R., Hynes, N. E., & Yarden, Y. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00356.x · Cited by 674
Prenzel, N., Fischer, O. M., Streit, S., Hart, S., & Ullrich, A. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080011 · Cited by 673
Self-citationPauletti, G., Dandekar, S., Rong, H., Ramos, L., Peng, H., Seshadri, R., & Slamon, D. J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.21.3651 · Cited by 670
Self-citationClinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
Schettini, F., Chic, N., Brasó-Maristany, F., Paré, L., Pascual, T., Conte, B., Martínez-Sáez, O., Adamo, B., Vidal, M., Barnadas, E., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-020-00208-2 · Cited by 670
Diéras, V., Miles, D., Verma, S., Pegram, M., Welslau, M., Baselga, J., Krop, I. E., Blackwell, K., Hoersch, S., Xu, J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30312-1 · Cited by 667
Research Review: Polygenic methods and their application to psychiatric traits
Wray, N. R., Lee, S. H., Mehta, D., Vinkhuyzen, A. A. E., Dudbridge, F., & Middeldorp, C. M. (2014) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12295 · Cited by 666
“ER +ve/ER – ve and over-expression of HER2 as a breast-cancer subtype (Wang et al., 2005; Slamon et al., 1987) or K-ras mutations in colorectal cancer and EGFR mutations in lung cancer, reviewed in (Ferraldeschi & Newman, 2011); however, other branches of medicine are able to supply measures of phenotypic heterogeneit…”
Xia, W., Mullin, R. J., Keith, B. R., Liu, L.-H., Ma, H., Rusnak, D. W., Owens, G., Alligood, K. J., & Spector, N. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205794 · Cited by 664
“…activated receptor mutants, transforms cells in vitro (Di Fiore et al., 1987; DiMarco et al., 1989; Hudziak et al., 1987; Qian et al., 1995), and correlates with a poorer clinical outcome in some breast cancers and a variety of other malignancies (Slamon et al., 1987, 1989; Bacus et al., 1994).”
BackgroundOwens, M. A., Horten, B. C., & Da Silva, M. M. (2004) · Clinical Breast Cancer · doi:10.3816/cbc.2004.n.011 · Cited by 657
HER2: Biology, Detection, and Clinical Implications
Gutierrez, C., & Schiff, R. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0454-rar.1 · Cited by 652
Glycoprotein glycosylation and cancer progression
Dennis, J. (1999) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(99)00167-1 · Cited by 652
RNA-binding proteins in human genetic disease
Lukong, K. E., Chang, K.-W., Khandjian, E. W., & Richard, S. (2008) · Trends in Genetics · doi:10.1016/j.tig.2008.05.004 · Cited by 646
“For example, epidermal growth factor receptor 2 (HER2) gene amplification is frequently observed in breast cancer [ 64 ], and activating mutations in the RAS oncogene are highly prevalent in colon cancer [65].”
ErbB Receptors: Directing Key Signaling Networks Throughout Life
Holbro, T., & Hynes, N. E. (2004) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121440 · Cited by 640
Di Fiore, P. P., Pierce, J. H., Fleming, T. P., Hazan, R., Ullrich, A., King, C. R., Schlessinger, J., & Aaronson, S. A. (1987) · Cell · doi:10.1016/0092-8674(87)90592-7 · Cited by 640
Self-citationAntitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase
Rabindran, S. K., Discafani, C. M., Rosfjord, E. C., Baxter, M., Floyd, M. B., Golas, J., Hallett, W. A., Johnson, B. D., Nilakantan, R., Overbeek, E., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2868 · Cited by 639
Targeted therapies: a new generation of cancer treatments.
Gerber, D. E. (2008) · PubMed · Cited by 637
Prognostic and Predictive Factors in Early-Stage Breast Cancer
Cianfrocca, M., & Goldstein, L. J. (2004) · The Oncologist · doi:10.1634/theoncologist.9-6-606 · Cited by 637
“It is amplified and/or overexpressed in approximately 30% of human breast tumors [ 52 ].”
BackgroundMolecular mechanisms underlying ErbB2/HER2 action in breast cancer
Harari, D., & Yarden, Y. (2000) · Oncogene · doi:10.1038/sj.onc.1203973 · Cited by 633
“%) in comedo forms of Ductal Carcinoma in situ (DCIS), a malignant ductal carcinoma that has not progressed beyond the basement membrane barrier (Barnes et al., 1992; Slamon et al., 1987; van de Vijver et al., 1988).”
BackgroundValabrega, G., Montemurro, F., & Aglietta, M. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl475 · Cited by 626
“Furthermore, HER2 overexpression is an adverse prognostic factor in women with breast cancer [6].”
BackgroundHudziak, R. M., Schlessinger, J., & Ullrich, A. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.20.7159 · Cited by 625
Self-citationMolecular biology in breast cancer: Intrinsic subtypes and signaling pathways
Eroles, P., Bosch, A., Alejandro Pérez-Fidalgo, J., & Lluch, A. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.11.005 · Cited by 624
“As specified in the previous section, HER-2+ tumors were historically classified as of poor prognosis.(30) However, the introduction of trastuzumab into the clinic, first in the metastatic disease(31)”
BackgroundTyrosine kinase – Role and significance in Cancer
Paul, M. K., & Mukhopadhyay, A. K. (2004) · International Journal of Medical Sciences · doi:10.7150/ijms.1.101 · Cited by 624
“The orphan receptor tyrosine kinase HER2 gene is amplified in breast cancer and acts as a major signaling partner for other EGFR family members leading to proliferation, differentiation, antiapoptosis [44] and tumor progression [45].”
BackgroundScheuer, W., Friess, T., Burtscher, H., Bossenmaier, B., Endl, J., & Hasmann, M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4597 · Cited by 622
Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.
Wright, C., Angus, B., Nicholson, S., Sainsbury, J. R. C., Cairns, J., Gullick, W. J., Kelly, P., Harris, A. L., & Horne, C. H. W. (1989) · PubMed · Cited by 622
Burris, H. A., Hurwitz, H. I., Dees, E. C., Dowlati, A., Blackwell, K. L., O'Neil, B., Marcom, P. K., Ellis, M. J., Overmoyer, B., Jones, S. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.584 · Cited by 619
Gianni, L., Dafni, U., Gelber, R. D., Azambuja, E., Muehlbauer, S., Goldhirsch, A., Untch, M., Smith, I., Baselga, J., Jackisch, C., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70033-x · Cited by 612
Berger, M. S., Locher, G. W., Saurer, S., Gullick, W. J., Waterfield, M. D., Groner, B., & Hynes, N. E. (1988) · PubMed · Cited by 611
The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
Ross, J. S., Fletcher, J. A., Linette, G. P., Stec, J., Clark, E., Ayers, M., Symmans, W. F., Pusztai, L., & Bloom, K. J. (2003) · The Oncologist · doi:10.1634/theoncologist.8-4-307 · Cited by 610
HER2 and Response to Paclitaxel in Node-Positive Breast Cancer
Hayes, D. F., Thor, A. D., Dressler, L. G., Weaver, D., Edgerton, S., Cowan, D., Broadwater, G., Goldstein, L. J., Martino, S., Ingle, J. N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071167 · Cited by 608
The ErbB receptors and their role in cancer progression
Holbro, T. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00099-x · Cited by 608
Nanocarriers for cancer-targeted drug delivery
Kumari, P., Ghosh, B., & Biswas, S. (2016) · Journal of Drug Targeting · doi:10.3109/1061186x.2015.1051049 · Cited by 607
“Human epidermal receptor-2 (HER-2) is over-expressed in a majority of patients with breast cancer [60–62].”
BackgroundNahta, R., Hung, M.-C., & Esteva, F. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3856 · Cited by 607
“The her-2 gene is amplified and overexpressed in 20–30% of invasive breast carcinomas, and is associated with increased metastatic potential and decreased overall survival (1, 2).”
BackgroundEmran, T. B., Shahriar, A., Mahmud, A. R., Rahman, T., Abir, M. H., Siddiquee, M. F. R., Ahmed, H., Rahman, N., Nainu, F., Wahyudin, E., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.891652 · Cited by 606
Abd El‐Rehim, D. M., Ball, G., Pinder, S. E., Rakha, E., Paish, C., Robertson, J. F. R., Macmillan, D., Blamey, R. W., & Ellis, I. O. (2005) · International Journal of Cancer · doi:10.1002/ijc.21004 · Cited by 606
“C-erbB-2 is recognized as an important molecular marker associated with poor overall survival and disease-free survival.(47) It has a therapeutic value in selecting cases more likely to be responsive to cerbB-2-directed immunotherapy.”
BackgroundTrastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer
Vu, T., & Claret, F. X. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00062 · Cited by 606
“HER2-positive breast cancer has the second-poorest prognosis among breast cancer subtypes and is correlated with lower disease-free and overall survival rates (Slamon et al., 1987; Tandon et al., 1989; Seshadri et al., 1993; Andrulis et al., 1998; Paik et al., 2000).”
BackgroundInfluentialTrastuzumab containing regimens for early breast cancer
Moja, L., Tagliabue, L., Balduzzi, S., Parmelli, E., Pistotti, V., Guarneri, V., & D'Amico, R. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006243.pub2 · Cited by 604
Bookman, M. A., Darcy, K. M., Clarke-Pearson, D., Boothby, R. A., & Horowitz, I. R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.104 · Cited by 598
KLIJN, J. G. M., BERNS, P. M. J. J., SCHMITZ, P. I. M., & FOEKENS, J. A. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-1-3 · Cited by 597
Moulder, S. L., Yakes, F. M., Muthuswamy, S. K., Bianco, R., Simpson, J. F., & Arteaga, C. L. (2001) · PubMed · Cited by 597
Aboagye, E. O., & Bhujwalla, Z. M. (1999) · PubMed · Cited by 596
The deaf and the dumb: the biology of ErbB-2 and ErbB-3
Citri, A. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00101-5 · Cited by 595
“ErbB-2 is overexpressed in a large proportion of breast and ovarian tumors (20–30%), primarily due to gene amplification [113,114].”
BackgroundKrop, I. E., Beeram, M., Modi, S., Jones, S. F., Holden, S. N., Yu, W., Girish, S., Tibbitts, J., Yi, J.-H., Sliwkowski, M. X., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2071 · Cited by 595
“Such tumors are considered HER2-positive and are associated with aggressive growth and poor clinical outcomes.(1,2) Trastuzumab (Herceptin; Genentech Inc, South San Francisco, CA), a humanized monoclonal antibody directed against the extracellular domain of HER2, is associated with substantial activity as a single age…”
BackgroundTrastuzumab emtansine: mechanisms of action and drug resistance
Barok, M., Joensuu, H., & Isola, J. (2014) · Breast Cancer Research · doi:10.1186/bcr3621 · Cited by 595
“In the past, patients with HER2-positive breast cancer generally had unfavorable outcome [2], but this changed radically after discovery of trastuzumab, a recombinant humanized monoclonal antibody that binds to the extracellular subdomain IV of HER2.”
BackgroundPaik, S., Hazan, R., Fisher, E. R., Sass, R. E., Fisher, B., Redmond, C., Schlessinger, J., Lippman, M. E., & King, C. R. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.1.103 · Cited by 594
Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer
Witton, C. J., Reeves, J. R., Going, J. J., Cooke, T. G., & Bartlett, J. M. (2003) · The Journal of Pathology · doi:10.1002/path.1370 · Cited by 590
“The effect of overexpression of HER2 due to amplification of the gene is well documented in breast cancer [1,4,5].”
BackgroundKonecny, G., Pauletti, G., Pegram, M., Untch, M., Dandekar, S., Aguilar, Z., Wilson, C., Rong, H.-M., Bauerfeind, I., Felber, M., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.2.142 · Cited by 588
Self-citationChromosome Aberrations and Cancer
Solomon, E., Borrow, J., & Goddard, A. D. (1991) · Science · doi:10.1126/science.1957167 · Cited by 584
Increasing Complexity of the Ras Signaling Pathway
Vojtek, A. B., & Der, C. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.19925 · Cited by 579
Kontermann, R. E., & Brinkmann, U. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.008 · Cited by 578
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity
Park, S., Jiang, Z., Mortenson, E. D., Deng, L., Radkevich-Brown, O., Yang, X., Sattar, H., Wang, Y., Brown, N. K., Greene, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.014 · Cited by 577
“The human epidermal growth factor receptor 2 (HER2, HER2/ neu, or ErbB-2) is overexpressed in 20%–30% of breast carcinomas and is associated with aggressive disease, a high recurrence rate, and reduced patient survival (Hudis, 2007; Kiessling et al., 2002; Meric-Bernstam and Hung, 2006; Slamon et al., 1987).”
BackgroundWen, D., Peles, E., Cupples, R., Suggs, S. V., Bacus, S. S., Luo, Y., Trail, G., Hu, S., Silbiger, S. M., Levy, R. B., et al. (1992) · Cell · doi:10.1016/0092-8674(92)90456-m · Cited by 577
Designed Ankyrin Repeat Proteins (DARPins): Binding Proteins for Research, Diagnostics, and Therapy
Plückthun, A. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134654 · Cited by 575
ErbB receptors: from oncogenes to targeted cancer therapies
Zhang, H., Berezov, A., Wang, Q., Zhang, G., Drebin, J., Murali, R., & Greene, M. I. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32278 · Cited by 574
Hirsch, F. R., Varella-Garcia, M., McCoy, J., West, H., Xavier, A. C., Gumerlock, P., Bunn, P. A., Franklin, W. A., Crowley, J., & Gandara, D. R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.2823 · Cited by 574
HER-2/neu oncogene protein and prognosis in breast cancer.
Tandon, A. K., Clark, G. M., Chamness, G. C., Ullrich, A., & McGuire, W. L. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.8.1120 · Cited by 574
Self-citationKeeping abreast of the mammary epithelial hierarchy and breast tumorigenesis
Visvader, J. E. (2009) · Genes & Development · doi:10.1101/gad.1849509 · Cited by 571
“While the luminal A and B subtypes are generally associated with a good prognosis, those tumors that overexpress HER2 (or exhibit amplification) usually display luminal features, but are associated with poor overall survival (Slamon et al. 1987).”
Background
Metadata
- Authors
- Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L.
- Affiliations
- University of California, Los Angeles (US)
- The University of Texas at San Antonio Health Science Center (US)
- Genentech (US)
- Venue
- Science
- Published
- 1987-01-09
- Volume
- 235
- Issue
- 4785
- Pages
- 177-182
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2141393790
- Cited by
- 11,760
- References
- 44
- Citations by year
- 2026: 209 · 2025: 230 · 2024: 301 · 2023: 309 · 2022: 302 · 2021: 346 · 2020: 336 · 2019: 325 · 2018: 344 · 2017: 395 · 2016: 416 · 2015: 433 · 2014: 486 · 2013: 549 · 2012: 459
- FWCI
- 103.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA36827, CA-30195)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- gene amplification, breast cancer, prognostic factors, relapse, overall survival, lymph node-positive disease, hormone receptor status, ErbB family, epidermal growth factor receptor
- MeSH terms
- Axilla, Breast Neoplasms, DNA, Female, Gene Amplification, Humans, Lymph Nodes, Neoplasm Recurrence, Local, Nucleic Acid Hybridization, Oncogenes, Prognosis, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.